Marko Cigler

Sep 7, 2023 | nature.com | Zuzanna Kozicka |Katherine A. Donovan |Marko Cigler |Jonathan L. Schmid-Burgk |Daniel Häussinger |Georg E. Winter | +4 more

AbstractMolecular glue degraders are an effective therapeutic modality, but their design principles are not well understood. Recently, several unexpectedly diverse compounds were reported to deplete cyclin K by linking CDK12–cyclin K to the DDB1–CUL4–RBX1 E3 ligase.